Greenwich LifeSciences GLSI
NASDAQ GLSI
$15.84 +0.21 (+1.34%)
As of: Sep 4, 2026 · 3:55 PM EDT

Greenwich LifeSciences (GLSI) Income towards Parent Company (2019 - 2026)

Greenwich LifeSciences' (GLSI) quarterly Income towards Parent Company came in at -$17.2 million in Q4 2025, down 5.48% YoY from -$18.2 million in Q4 2024, and down 314.23% on a QoQ basis from -$4.2 million in Q3 2025.

Analysis

Greenwich LifeSciences (GLSI) Income towards Parent Company (2019 - 2026) Analysis & Trends

Greenwich LifeSciences (GLSI) has 7 years of Income towards Parent Company data on file, last reported at -$17.2 million in Q4 2025.

  • Quarterly Income towards Parent Company fell 5.48% year-over-year to -$17.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$28.6 million (down 19.04% YoY) and the FY2025 annual result came in at -$28.6 million, down 19.04% from the prior year.
  • Income towards Parent Company declined to -$17.2 million in Q4 2025, from -$4.2 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of -$597008.0 in Q1 2021 to a low of -$17.2 million in Q4 2025.
  • A 5-year average of -$4.4 million and a median of -$3.0 million in 2024 frame the typical range for Income towards Parent Company.
  • Annual changes were most pronounced in 2022 — Income towards Parent Company sank 511.25% — and 2023, when it soared 44.75%.
  • Tracing GLSI's Income towards Parent Company over 5 years: stood at -$3.9 million in 2021, then sank by 52.98% to -$5.9 million in 2022, then fell by 22.34% to -$7.3 million in 2023, then slumped by 124.83% to -$16.3 million in 2024, then fell by 5.48% to -$17.2 million in 2025.
  • The last three Income towards Parent Company figures came in at -$17.2 million (Q4 2025), -$4.2 million (Q3 2025), and -$4.0 million (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Greenwich LifeSciences 231.59 Mn 231.59 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -5.66 Mn
Dec 31, 2025 -7.92 Mn
Sep 30, 2025 -4.15 Mn
Jun 30, 2025 -4.03 Mn
Mar 31, 2025 -2.74 Mn
Dec 31, 2024 -9.67 Mn
Sep 30, 2024 -2.67 Mn
Jun 30, 2024 -2.61 Mn
Mar 31, 2024 -2.47 Mn
Dec 31, 2023 -2.75 Mn
Sep 30, 2023 -2.39 Mn
Jun 30, 2023 -1.63 Mn
Mar 31, 2023 -2.12 Mn
Dec 31, 2022 -2.79 Mn
Sep 30, 2022 -2.32 Mn
Jun 30, 2022 -746,073.00
Mar 31, 2022 -1.97 Mn
Dec 31, 2021 -2.36 Mn
Sep 30, 2021 -863,118.00
Jun 30, 2021 -749,745.00